Ono Pharmaceutical Co., Ltd. (TYO:4528)
1,557.50
-11.50 (-0.73%)
May 9, 2025, 3:30 PM JST
Ono Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 204,567 | 166,141 | 96,135 | 69,112 | 61,045 | Upgrade
|
Short-Term Investments | 4,479 | - | 20 | 60 | 2,978 | Upgrade
|
Cash & Short-Term Investments | 209,046 | 166,141 | 96,155 | 69,172 | 64,023 | Upgrade
|
Cash Growth | 25.82% | 72.78% | 39.01% | 8.04% | -8.04% | Upgrade
|
Receivables | 135,022 | 136,066 | 114,396 | 99,788 | 84,269 | Upgrade
|
Inventory | 74,864 | 48,629 | 44,814 | 41,817 | 39,151 | Upgrade
|
Prepaid Expenses | - | 14,699 | 10,465 | 10,952 | 10,003 | Upgrade
|
Other Current Assets | 36,172 | 48,061 | 79,271 | 59,537 | 50,196 | Upgrade
|
Total Current Assets | 455,104 | 413,596 | 345,101 | 281,266 | 247,642 | Upgrade
|
Property, Plant & Equipment | 105,721 | 104,752 | 108,420 | 112,131 | 113,866 | Upgrade
|
Long-Term Investments | 100,975 | 297,170 | 324,178 | 255,997 | 281,393 | Upgrade
|
Goodwill | 21,186 | - | - | - | - | Upgrade
|
Other Intangible Assets | 330,041 | 57,288 | 69,134 | 64,734 | 70,322 | Upgrade
|
Long-Term Deferred Tax Assets | 51,020 | 40,863 | 35,604 | 25,074 | 33,619 | Upgrade
|
Other Long-Term Assets | -1 | -1 | - | 1 | - | Upgrade
|
Total Assets | 1,064,046 | 913,668 | 882,437 | 739,203 | 746,842 | Upgrade
|
Accounts Payable | 89,329 | 60,691 | 66,794 | 49,689 | 39,163 | Upgrade
|
Accrued Expenses | - | 13,493 | 11,726 | 10,824 | 10,393 | Upgrade
|
Short-Term Debt | 30,000 | - | - | - | - | Upgrade
|
Current Portion of Leases | 3,178 | 2,310 | 2,490 | 2,301 | 2,023 | Upgrade
|
Current Income Taxes Payable | 4,058 | 24,518 | 40,896 | 2,284 | 20,804 | Upgrade
|
Other Current Liabilities | 21,731 | 2,612 | 1,023 | 828 | 21,350 | Upgrade
|
Total Current Liabilities | 148,296 | 103,624 | 122,929 | 65,926 | 93,733 | Upgrade
|
Long-Term Debt | 105,000 | - | - | - | - | Upgrade
|
Long-Term Leases | 8,500 | 6,552 | 6,678 | 6,501 | 7,030 | Upgrade
|
Long-Term Deferred Tax Liabilities | 10,817 | 1,013 | 983 | 1,009 | 1,052 | Upgrade
|
Other Long-Term Liabilities | 591 | 580 | 684 | 771 | 814 | Upgrade
|
Total Liabilities | 275,844 | 115,063 | 134,624 | 77,529 | 105,685 | Upgrade
|
Common Stock | 17,358 | 17,358 | 17,358 | 17,358 | 17,358 | Upgrade
|
Additional Paid-In Capital | 17,458 | 17,458 | 17,080 | 17,241 | 17,231 | Upgrade
|
Retained Earnings | 790,908 | 768,183 | 709,890 | 644,754 | 583,363 | Upgrade
|
Treasury Stock | -63,063 | -63,233 | -54,161 | -74,683 | -44,705 | Upgrade
|
Comprehensive Income & Other | 19,790 | 53,195 | 51,702 | 51,236 | 62,300 | Upgrade
|
Total Common Equity | 782,451 | 792,961 | 741,869 | 655,906 | 635,547 | Upgrade
|
Minority Interest | 5,751 | 5,644 | 5,944 | 5,768 | 5,610 | Upgrade
|
Shareholders' Equity | 788,202 | 798,605 | 747,813 | 661,674 | 641,157 | Upgrade
|
Total Liabilities & Equity | 1,064,046 | 913,668 | 882,437 | 739,203 | 746,842 | Upgrade
|
Total Debt | 146,678 | 8,862 | 9,168 | 8,802 | 9,053 | Upgrade
|
Net Cash (Debt) | 62,368 | 157,279 | 86,987 | 60,370 | 54,970 | Upgrade
|
Net Cash Growth | -60.35% | 80.81% | 44.09% | 9.82% | -10.27% | Upgrade
|
Net Cash Per Share | 132.61 | 327.64 | 178.12 | 121.58 | 110.12 | Upgrade
|
Filing Date Shares Outstanding | 469.76 | 469.65 | 488.33 | 488.31 | 499.21 | Upgrade
|
Total Common Shares Outstanding | 469.76 | 469.65 | 488.33 | 488.24 | 499.14 | Upgrade
|
Working Capital | 306,808 | 309,972 | 222,172 | 215,340 | 153,909 | Upgrade
|
Book Value Per Share | 1665.65 | 1688.42 | 1519.18 | 1343.40 | 1273.28 | Upgrade
|
Tangible Book Value | 431,224 | 735,673 | 672,735 | 591,172 | 565,225 | Upgrade
|
Tangible Book Value Per Share | 917.97 | 1566.44 | 1377.61 | 1210.81 | 1132.39 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.